Assessing Maximus after recent share price moves

Maximus (MMS) has seen a mix of short term moves, with a 1 day return near flat, a negative week, and stronger month and past 3 months performance. The stock recently closed at $94.44.

That recent pullback over the week comes after a steady stretch, with a 30 day share price return of 9.22% and a 1 year total shareholder return of 27.43%, suggesting momentum has generally been positive over the past year.

If Maximus has you thinking about other ways to put capital to work, this could be a good moment to broaden your search and look at healthcare stocks.

With Maximus trading at $94.44, alongside an intrinsic discount estimate of 46.72% and a value score of 5, the key question is whether you are looking at genuine undervaluation or a price that already reflects future growth.

Most Popular Narrative: 14.1% Undervalued

Maximus' most followed narrative pegs fair value at $110, above the recent $94.44 close. This is why it frames the shares as undervalued.

The company's ongoing investments in digital, workflow automation, and AI (notably for complex health and claims processing), along with recent inorganic growth and an expanded pipeline in federal and state markets, are cited as laying the groundwork for sustainable earnings growth above the rate of revenue growth, as evidenced by recent margin performance and forward guidance.

Analysts are tying this valuation to a specific mix of future revenue growth, margin expansion, and a lower earnings multiple than many peers enjoy today. Want to see how those moving parts fit together and what assumptions sit behind that $110 fair value tag? The full narrative breaks down the numbers in plain language so you can test whether they line up with your own expectations.

Result: Fair Value of $110 (UNDERVALUED)

However, the story can change quickly if large government contracts are delayed or if agencies adopt more automation internally, which could reduce demand for Maximus' services.

Build Your Own Maximus Narrative

If this view does not quite fit how you see Maximus, or you prefer to test the data yourself, you can build a personalised thesis in minutes with Do it your way.

A great starting point for your Maximus research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Maximus is on your radar, do not stop there. A broader watchlist can help you spot opportunities you might otherwise miss.

• Target potential value opportunities early by scanning these 875 undervalued stocks based on cash flows that may be trading below what their cash flows suggest.
• Ride major tech shifts by checking out these 24 AI penny stocks that connect artificial intelligence themes with listed companies.
• Secure potential income streams by reviewing these 12 dividend stocks with yields > 3% that offer yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.